Slow and steady wins the race: precision medicine for low risk endometrial cancer
- PMID: 32376741
- DOI: 10.1136/ijgc-2020-001467
Slow and steady wins the race: precision medicine for low risk endometrial cancer
Keywords: uterine cancer.
Conflict of interest statement
Competing interests: Kurnit: Consulting – LEAP Therapeutics. Westin: Research support to institutions – AstraZeneca, ArQule, Clovis Oncology, GSK/Tesaro, Roche/Genentech, Bayer, Novartis, Cotinga Pharmaceuticals. Consulting: AstraZeneca, Clovis Oncology, GSK/Tesaro, Roche/Genentech, Novartis, Eisai, Merck, Pfizer, Circulogene
Comment on
-
Clinical patterns and genomic profiling of recurrent 'ultra-low risk' endometrial cancer.Int J Gynecol Cancer. 2020 Jun;30(6):717-723. doi: 10.1136/ijgc-2020-001241. Epub 2020 May 5. Int J Gynecol Cancer. 2020. PMID: 32376737 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
